Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 European Society of Cardiology Congress

Kartik Gupta, Colin Hinkamp, Tyler Andrews, Chelsea Meloche, Abdul Mannan Khan Minhas, Leandro Slipczuk, Elizabeth Vaughan, Fatima Zohra Habib, Sana Sheikh, Dinesh Kalra, Salim S. Virani

Research output: Contribution to journalReview articlepeer-review


Purpose of Review: To summarize selected late-breaking science on cardiovascular (CV) disease prevention presented at the 2023 European Society of Cardiology (ESC) congress. Recent Findings: The NATURE-PARADOX was a naturally randomized trial that used genetic data from the UK Biobank registry to create “cumulative exposure to low-density lipoprotein-cholesterol (LDL-C)” biomarker and evaluate its association with major CV events regardless of plasma LDL-C levels or age. Safety and efficacy data of inclisiran, a PCSK9-interfering mRNA (PCSK9i) administered subcutaneously twice annually, were presented. Data on two new PCSK9is were presented, recaticimab, an oral drug, and lerodalcibep, a subcutaneous drug with a slightly different architecture than currently available PSCK9is. A phase 1 trial on muvalaplin, an oral lipoprotein (a) inhibitor, was presented. An atherosclerotic CV disease (ASCVD) risk prediction algorithm for the Asian population using SCORE2 data was presented. Long-term follow-up of patients enrolled in the CLEAR outcomes trial showed sustained and more significant ASCVD risk reduction with bempedoic acid in high-risk patients. Summary: The late-breaking clinical science at the 2023 congress of the ESC extends the known safety and efficacy data of a PCSK9i with the introduction of new drugs in this class. Using cumulative exposure to LDL-C rather than a single value will help clinicians tailor the LDL-C reduction strategy to individual risk and is an important step towards personalized medicine.

Original languageEnglish (US)
Pages (from-to)965-978
Number of pages14
JournalCurrent Atherosclerosis Reports
Issue number12
StatePublished - Dec 2023
Externally publishedYes


  • ESC
  • OCEAN(a)
  • PCSK9

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 European Society of Cardiology Congress'. Together they form a unique fingerprint.

Cite this